|
Volumn 61, Issue 2, 2001, Pages 759-763
|
Pretreatment with paclitaxel enhances Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CYCLOHEXIMIDE;
CYTOCHROME C;
DEATH RECEPTOR 4;
DEATH RECEPTOR 5;
DOCETAXEL;
FAS LIGAND;
PACLITAXEL;
TUMOR NECROSIS FACTOR;
TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC ACTIVITY;
APOPTOSIS;
ARTICLE;
CANCER CELL;
CONTROLLED STUDY;
DOSE RESPONSE;
HUMAN;
HUMAN CELL;
PRIORITY JOURNAL;
PROSTATE CANCER;
PROTEIN ANALYSIS;
PROTEIN PROCESSING;
RECEPTOR UPREGULATION;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
APOPTOSIS;
APOPTOSIS REGULATORY PROTEINS;
BLOTTING, WESTERN;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG SYNERGISM;
HUMANS;
MALE;
MEMBRANE GLYCOPROTEINS;
PACLITAXEL;
PROSTATIC NEOPLASMS;
RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;
RECEPTORS, TUMOR NECROSIS FACTOR;
TNF-RELATED APOPTOSIS-INDUCING LIGAND;
TUMOR CELLS, CULTURED;
TUMOR NECROSIS FACTOR-ALPHA;
UP-REGULATION;
|
EID: 0035863523
PISSN: 00085472
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (200)
|
References (25)
|